Opthea Limited (NASDAQ:OPT – Free Report) – Equities research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Opthea in a report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($1.15) per share for the year, up from their previous estimate of ($1.20). The consensus estimate for Opthea’s current full-year earnings is ($1.40) per share. Leerink Partnrs also issued estimates for Opthea’s FY2026 earnings at ($1.05) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $1.60 EPS.
Separately, HC Wainwright lowered their price target on Opthea from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.
Opthea Trading Down 0.8 %
OPT stock opened at $4.99 on Friday. Opthea has a fifty-two week low of $1.60 and a fifty-two week high of $5.45. The stock has a fifty day moving average of $3.61 and a 200-day moving average of $3.06.
Opthea Company Profile
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Featured Articles
- Five stocks we like better than Opthea
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Survey Reveals: America’s Most Coveted Businesses in 2024
- 3 Monster Growth Stocks to Buy Now
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Why Are These Companies Considered Blue Chips?
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.